Use the journals feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#21
JOURNAL ARTICLE
Yong'an Jiang, Peng Chen, JiaWei Liang, JiaHong Cai, Yi Zhang, HengYi Fan, RaoRao Yuan, Wenxin Zheng, ShiQi Cheng, Yan Zhang
BACKGROUND: The clinical effect of postoperative radiotherapy (PORT) in non-malignant meningioma (NMM) has not been well explored. METHODS: A total of 8629 patients with NMM (surgery alone group: n = 7716, postoperative radiotherapy group: n = 913) were obtained from the Surveillance, Epidemiology, and End Results database. Patient profiles were matched by 1:1 propensity score matching (PSM). Logistic regression analysis was performed to identify factors associated with PORT versus surgery alone (SA)...
May 31, 2023: Cancer Medicine
#22
JOURNAL ARTICLE
Jinyi Xu, Zhiyi Yao, Guoliang Liao, Xi OuYang, Shengxun Mao, Jiaqing Cao, Bin Lai
BACKGROUND: Small intestine cancer (SIC) is difficult to diagnose early and presents a poor prognosis due to distant metastasis. This study aimed to develop nomograms for diagnosing and assessing the prognosis of SIC with distant metastasis. METHODS: Patients diagnosed with SIC between 2010 and 2015 were included from the Surveillance, Epidemiology and End Results database. Univariate and multifactor analysis determined independent risk factors for distant metastasis and prognostic factors for overall and cancer-specific survival...
May 31, 2023: Cancer Medicine
#23
JOURNAL ARTICLE
Wei Guo, Tao Zhang, Runze Li, Xiaoxi Chen, Jiaohui Pang, Hua Bao, Xue Wu, Yang Shao, Bin Qiu, Shugeng Gao, Jie He
BACKGROUND: Locoregional recurrence is of high risk and is associated with a poor prognosis in terms of OS for non-small cell lung cancer (NSCLC). Local control is essential for radical cure of NSCLC. Previous studies have investigated the clinicopathological risk factors for locoregional recurrence, but the genomic biomarkers associated with locoregional recurrence have been inadequately studied. METHODS: A total of 118 patients who underwent tumor resection with mutation-detected tumor specimens were included...
May 29, 2023: Cancer Medicine
#24
JOURNAL ARTICLE
Jenerius A Aminawung, Pamela R Soulos, Oluwadamilola T Oladeru, Hsiu-Ju Lin, Lou Gonsalves, Lisa B Puglisi, Sirad Hassan, Ilana B Richman, Emily A Wang, Cary P Gross
BACKGROUND: Cancer incidence among individuals with incarceration exposure has been rarely studied due to the absence of linked datasets. This study examined cancer incidence during incarceration and postincarceration compared to the general population using a statewide linked cohort. METHODS: We constructed a retrospective cohort from a linkage of state tumor registry and correctional system data for Connecticut residents from 2005 to 2016, and identified cancers diagnosed during and within 12 months postincarceration...
May 29, 2023: Cancer Medicine
#25
REVIEW
Jing Li, Xin Wang, Mudan Ren, Shuixiang He, Yan Zhao
Hepatocellular carcinoma (HCC) is a common malignant tumor with insidious early symptoms, easy metastasis, postoperative recurrence, poor drug efficacy, and a high drug resistance rate when surgery is missed, leading to a low 5-year survival rate. Research on the pathogenesis and drugs is particularly important for clinical treatment. Animal models are crucial for basic research, which is conducive to studying pathogenesis and drug screening more conveniently and effectively. An appropriate animal model can better reflect disease occurrence and development, and the process of anti-tumor immune response in the human body...
May 29, 2023: Cancer Medicine
#26
JOURNAL ARTICLE
Yansong Zheng, Jing Dong, Xue Yang, Ping Shuai, Yongli Li, Hailin Li, Shengyong Dong, Yan Gong, Miao Liu, Qiang Zeng
BACKGROUND: Many people were found with pulmonary nodules during physical examinations. It is of great practical significance to discriminate benign and malignant nodules by using data mining technology. METHODS: The subjects' demographic data, baseline examination results, and annual follow-up low-dose spiral computerized tomography (LDCT) results were recorded. The findings from annual physical examinations of positive nodules, including highly suspicious nodules and clinically tentative benign nodules, was analyzed...
May 29, 2023: Cancer Medicine
#27
JOURNAL ARTICLE
Christabel K Cheung, Haelim Lee, Nina Jackson Levin, Eunju Choi, Valentina A Ross, Yimin Geng, Bria N Thomas, Michael E Roth
BACKGROUND: Adolescent and young adult cancer patients (AYAs) who are sexual and gender minorities (SGM) are a rapidly increasing population that experiences unmet cancer-related needs. Despite emerging awareness, little is known about cancer care and outcomes for this vulnerable population. The purpose of this scoping review was to explore current knowledge and gaps in the literature on cancer care and outcomes for AYAs who identify as SGM. METHODS: We reviewed empirical knowledge on SGM AYAs by identifying, describing, and critically appraising the literature to date...
May 28, 2023: Cancer Medicine
#28
JOURNAL ARTICLE
Grant R Williams, Mackenzie Fowler, Smith Giri, Chen Dai, Christian Harmon, Mustafa Al-Obaidi, Coryn Stephenson, Kira Bona, Wendy Landier, Smita Bhatia, Julie Wolfson
BACKGROUND: Basic resource needs related to transportation, housing, food, and medications are important social determinants of health and modifiable indicators of poverty, but their role in modifying the risk of frailty and health-related quality of life (HRQoL) remains unknown. The goal of our study was to examine the prevalence of unmet basic needs and their association with frailty and HRQoL in a cohort of older adults with cancer. METHODS: The CARE registry prospectively enrolls older adults (≥60 years) with cancer...
May 28, 2023: Cancer Medicine
#29
REVIEW
Isabel Mosquera, Adam Todd, Mirza Balaj, Li Zhang, Sara Benitez Majano, Keitly Mensah, Terje Andreas Eikemo, Partha Basu, Andre L Carvalho
BACKGROUND: Inequalities in cancer incidence and mortality can be partly explained by unequal access to high-quality health services, including cancer screening. Several interventions have been described to increase access to cancer screening, among them patient navigation (PN), a barrier-focused intervention. This systematic review aimed to identify the reported components of PN and to assess the effectiveness of PN to promote breast, cervical and colorectal cancer screening. METHODS: We searched Embase, PubMed and Web of Science Core Collection databases...
May 28, 2023: Cancer Medicine
#30
JOURNAL ARTICLE
Mallikarjuna Siraganahalli Eshwaraiah, Aparna Gunda, Govind Babu Kanakasetty, Manjiri M Bakre
BACKGROUND: Assessment of Ki67 by immunohistochemistry (IHC) has limited utility in clinical practice owing to analytical validity issues. According to International Ki67 Working Group (IKWG) guidelines, treatment should be guided by a prognostic test in patients expressing intermediate Ki67 range, >5%-<30%. The objective of the study is to compare the prognostic performance of CanAssist Breast (CAB) with that of Ki67 across various Ki67 prognostic groups. METHODS: The cohort had 1701 patients...
May 28, 2023: Cancer Medicine
#31
JOURNAL ARTICLE
Takashi Kasai, Kiyoshi Mori, Yoichi Nakamura, Nobuhiko Seki, Yasuko Ichikawa, Haruhiro Saito, Tetsuro Kondo, Kazuo Nishikawa, Satoshi Otsu, Akihiro Bessho, Hiroshi Tanaka, Hiroyuki Yamaguchi, Takayuki Kaburagi, Hisao Imai, Keita Mori, Junya Ohtake, Hiroaki Okamoto
INTRODUCTION: Cisplatin plus pemetrexed followed by pemetrexed is an efficacious platinum combination regimen for advanced non-squamous, non-small cell lung cancer (NSCLC). Data regarding the addition of bevacizumab, especially in maintenance treatment, are insufficient. METHODS: Eligibility criteria included: no prior chemotherapy; advanced, non-squamous, NSCLC; performance status ≤1; and epidermal growth factor receptor mutation-negative. Patients (N = 108) received induction chemotherapy with cisplatin, pemetrexed, and bevacizumab every 3 weeks for four cycles, and tumor response was needed to confirm four-week response duration...
May 24, 2023: Cancer Medicine
#32
JOURNAL ARTICLE
Yuqian Yan, Jesús López-Alcalde, Linxin Zhang, Alexander R Siebenhüner, Claudia M Witt, Jürgen Barth
PURPOSE: To assess the effectiveness and safety of acupuncture for the prevention of chemotherapy-induced nausea and vomiting (CINV), with a specific intention on exploring sources of between-study variation in treatment effects. METHODS: MEDLINE, EMBASE, Cochrane CENTRAL, CINAHL, Chinese Biomedical Literature Database, VIP Chinese Science and Technology Periodicals Database, China National Knowledge Infrastructure, and Wanfang were searched to identify randomized controlled trials (RCTs) that compared acupuncture to sham acupuncture or usual care (UC)...
May 24, 2023: Cancer Medicine
#33
JOURNAL ARTICLE
Shan Wu, Chaotao Tang, Qing-Wei Zhang, Qian Zhuang, Xin Ye, Jie Xia, Yan Shi, Min Ning, Zhi-Xia Dong, Xin-Jian Wan
BACKGROUND: Gastric cancer (GC) is one of most common cancers worldwide. Several studies have suggested that Rab31 functions as a membrane vesicle transport regulator; however, the mechanism by which RAB31 regulates exosome secretion and promotes metastasis remains to be clarified. METHODS: We examined the expression of RAB31 protein and mRNA in GC tissue samples via immunohistochemistry and reverse transcription-polymerase chain reaction assays, respectively. We elucidated the function of RAB31 in GC cells by constructing a cell model and a pulmonary metastatic model of GC with overexpression of RAB31...
May 24, 2023: Cancer Medicine
#34
JOURNAL ARTICLE
Qiang Song, Wenjin Zhang, Dan Shi, Zhiliang Zhang, Qiurong Zhao, Mengyuan Wang, Man Huang, Juanjuan Meng, Wei Cui, Xiaohe Luo
INTRODUCTION: The cannabinoid receptor 2 (CB2) is mainly involved in the immune system. However, although CB2 has been reported to play an anti-tumor function in breast cancer (BC), its specific mechanism in BC remains unclear. METHODS: We examined the expression and prognostic significance of CB2 in BC tissues by qPCR, second-generation sequencing, western blot, and immunohistochemistry. We assessed the impacts of overexpression and a specific agonist of CB2 on the growth, proliferation, apoptosis, and drug resistance of BC cells in vitro and in vivo using CCK-8, flow cytometry, TUNEL staining, immunofluorescence, tumor xenografts, western blot, and colony formation assays...
May 23, 2023: Cancer Medicine
#35
JOURNAL ARTICLE
Courtney P Williams, Heather N Platter, Amy J Davidoff, Robin C Vanderpool, Maria Pisu, Janet S de Moor
BACKGROUND: Understanding cancer survivors' health insurance decision-making is needed to improve insurance choice, potentially resulting in reduced financial hardship. METHODS: This explanatory mixed methods study assessed health insurance decision-making in cancer survivors. Health Insurance Literacy Measure (HILM) captured HIL. Quantitative eye-tracking data collected from two simulated health insurance plan choice sets gauged dwell time (seconds), or interest, in benefits...
May 23, 2023: Cancer Medicine
#36
JOURNAL ARTICLE
Ane Sørlie Kvaerner, Astrid Riseth Andersen, Hege Berg Henriksen, Markus Dines Knudsen, Anne Marte Wetting Johansen, Anette Hjartåker, Siv Kjølsrud Bøhn, Ingvild Paur, Gro Wiedswang, Sigbjørn Smeland, Trine B Rounge, Rune Blomhoff, Paula Berstad
BACKGROUND: While adherence to cancer prevention recommendations is linked to lower risk of colorectal cancer (CRC), few have studied associations across the entire spectrum of colorectal carcinogenesis. Here, we studied the relationship of the standardized 2018 World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR) Score for cancer prevention recommendations with detection of colorectal lesions in a screening setting. As a secondary objective, we examined to what extent the recommendations were being followed in an external cohort of CRC patients...
May 22, 2023: Cancer Medicine
#37
JOURNAL ARTICLE
Weidong Lin, Kunpeng Wang, Jinggang Mo, Liezhi Wang, Zhenshun Song, Hao Jiang, Cong Wang, Chong Jin
BACKGROUND: Liver cancer is a highly malignant disease and the third leading cause of cancer death worldwide. Abnormal activation of PI3K/Akt signaling is common in cancer, but whether phosphoinositide-3-kinase regulatory subunit 3 (PIK3R3) plays a role in liver cancer is largely unexplored. METHODS: We determined the expression of PIK3R3 in liver cancer by using TCGA data and our clinical samples and knocked it down by siRNA or overexpressing it by the lentivirus vector system...
May 22, 2023: Cancer Medicine
#38
JOURNAL ARTICLE
Nianyi Li, Pei Lin, Zhuang Zuo, M James You, Wen Shuai, Robert Orlowski, Elisabet E Manasanch, Shaoying Li, Jie Xu, Sofia Garces, Fatima Zahra Jelloul, Zhenya Tang, Wei Wang, L Jeffrey Medeiros, C Cameron Yin
BACKGROUND: Mutations in the RAS-MAPK pathway, such as KRAS, NRAS, and BRAF, are known as high-risk factors associated with poor prognosis in patients with various cancers, but studies in myeloma have yielded mixed results. METHODS: We describe the clinicopathologic, cytogenetic, molecular features, and outcomes of 68 patients with RAS/BRAF-mutated myeloma, and compare with 79 patients without any mutations. RESULTS: We show that KRAS, NRAS, and BRAF were mutated in 16%, 11%, and 5% of cases, respectively...
May 22, 2023: Cancer Medicine
#39
JOURNAL ARTICLE
Sarah Reddy, Suleyman Yasin Goksu, Nina N Sanford, Radhika Kainthla, David Hsiehchen, Aravind Sanjeevaiah, Amy L Jones, Georgios Karagkounis, Salwan Al Mutar, Chul Ahn, Muhammad S Beg, Syed M Kazmi
BACKGROUND: While the incidence of cholangiocarcinoma is rising, little is known about young-onset disease. We compared clinical characteristics and outcomes between patients with young-onset cholangiocarcinoma, diagnosed between the ages of 18 and <50 years, and patients with typical-onset cholangiocarcinoma, diagnosed at age 50 years or greater. METHODS: We used the National Cancer Database to identify patients with young-onset cholangiocarcinoma (n = 2520) and typical-onset cholangiocarcinoma (n = 23,826)...
May 22, 2023: Cancer Medicine
#40
JOURNAL ARTICLE
Teresa Bernal, Ainhoa Fernández Moreno, Almudena de LaIglesia, Celina Benavente, Ana García-Noblejas, Daniel García Belmonte, Rosalía Riaza, Olga Salamero, Maria Angeles Foncillas, Alicia Roldán, Víctor Noriega Concepción, Laura Llorente González, Juan Miguel Bergua Burgués, Soraya Lorente de Uña, Gabriela Rodríguez-Macías, Adolfo de la Fuente Burguera, Maria José García Pérez, Jose Luis López-Lorenzo, Pilar Martínez, Concepción Aláez, Marta Callejas, Carmen Martínez-Chamorro, José Rifón Roca, Lourdes Amador Barciela, Armando V Mena Durán, Karoll Gómez Correcha, Esperanza Lavilla Rubira, María Luz Amigo, Ferran Vall-Llovera, Ana Garrido, María García-Fortes, Dunia de Miguel Llorente, Anastasia Aules Leonardo, Carlos Cervero, Rosa Coll Jordá, Manuel M Pérez-Encinas, Marta Polo Zarzuela, Angela Figuera, Guillermo Rad, David Martínez-Cuadrón, Pau Montesinos
BACKGROUND: CPX-351 is approved for the treatment of therapy related acute myeloid leukemia (t-AML) and AML with myelodysplastic related changes (MRC-AML). The benefits of this treatment over standard chemotherapy has not been addressed in well matched cohorts of real-life patients. METHODS: Retrospective analysis of AML patients treated with CPX-351 as per routine practice. A propensity score matching (PSM) was used to compare their main outcomes with those observed in a matched cohort among 765 historical patients receiving intensive chemotherapy (IC), all of them reported to the PETHEMA epidemiologic registry...
May 22, 2023: Cancer Medicine
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
